Olanzapine
- Generic Name
- Olanzapine
- Brand Names
- Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20N4S
- CAS Number
- 132539-06-1
- Unique Ingredient Identifier
- N7U69T4SZR
- Background
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resemb...
- Indication
Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.
...
- Associated Conditions
- Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
- Conditions
- Interventions
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 426
- Registration Number
- NCT03187769
- Locations
- 🇬🇧
Alkermes Investigational Site, Maidstone, United Kingdom
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 30
- Registration Number
- NCT03137121
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Hospital Sisters Health System (HSHS) St. Vincent Hospital, Green Bay, Wisconsin, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 200
- Registration Number
- NCT03118986
- Locations
- 🇨🇦
Cancer Care Manitoba, Winnipeg, Manitoba, Canada
🇺🇸Columbia University/Morgan Stanley Children's Hospital, New York, New York, United States
🇨🇦Centre Hospitalier Universitaire Sainte-Justine,, Montréal, Quebec, Canada
Olanzapine for the Treatment of Refractory Chronic Nausea and Vomiting
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- Johns Hopkins University
- Registration Number
- NCT02977741
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of CIN
- Conditions
- Interventions
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- Hee Jun Kim
- Target Recruit Count
- 48
- Registration Number
- NCT02970643
An Insulin Sensitivity Study in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02922426
- Locations
- 🇺🇸
Alkermes Investigational Site, Chula Vista, California, United States
Long-acting Paliperidone Palmitate Injection and Olanzapine for Schizophrenia
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Beijing HuiLongGuan Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02918825
- Locations
- 🇨🇳
Beijing HuiLongGuan Hospital, Beijing, China
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Conditions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 1037352
- Registration Number
- NCT02893371
- Locations
- 🇺🇸
Christophe G Lambert, Albuquerque, New Mexico, United States
Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study
- First Posted Date
- 2016-08-10
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 221
- Registration Number
- NCT02861859
- Locations
- 🇨🇦
The Ottawa Hospital Research Institute Cance Center, Ottawa, Ontario, Canada
Trial and Follow-up of the Efficacy of Two-stage Integrated Treatment for Chinese Schizophrenia Inpatients
- Conditions
- Interventions
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- Guangzhou Psychiatric Hospital
- Target Recruit Count
- 170
- Registration Number
- NCT02850445
- Locations
- 🇨🇳
Guangzhou psychitric hosptial, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.